YU20095A - Mgdf polipeptidi i postupci za njihovu izradu - Google Patents

Mgdf polipeptidi i postupci za njihovu izradu

Info

Publication number
YU20095A
YU20095A YU20095A YU20095A YU20095A YU 20095 A YU20095 A YU 20095A YU 20095 A YU20095 A YU 20095A YU 20095 A YU20095 A YU 20095A YU 20095 A YU20095 A YU 20095A
Authority
YU
Yugoslavia
Prior art keywords
mgdf
methods
preparation
growth
proteins
Prior art date
Application number
YU20095A
Other languages
English (en)
Inventor
Timothy D. Bartley
Jakob M. Bogenberg
Robert A. Bosselman
Pamela Hunt
Barbry B. Samal
B.O. Kinstler
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/321,488 external-priority patent/US5795569A/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of YU20095A publication Critical patent/YU20095A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Opisani su novi proteini, tzv. MGDF proteini (MGDF, od engl. medakaryocyte growth and development factorid, ili MPI ligand) koji imaju biološku aktivnost stimulisanja rasta i pojačavanja diferencijacije ili sazrevanja megakariocita, sa krajnjim rezultatom stvaranja trombocita. Opisani su i derivati MGDF, koji se sastoje od molekula MGDF vezanog sa polimerima rastvorljivim u vodi, kao što je polietilen glikol, kao i postupci za njihovo dobijanje. Takodje su opisani postupci za dobijanje MGDF u homogenom obliku iz prirodnih izvora i postupci za njihovu proizvodnju tehnikama rekombinantnog genetskog inženjeringa.
YU20095A 1994-03-31 1995-03-30 Mgdf polipeptidi i postupci za njihovu izradu YU20095A (sh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22176894A 1994-03-31 1994-03-31
US25262894A 1994-05-31 1994-05-31
US08/321,488 US5795569A (en) 1994-03-31 1994-10-12 Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US34778094A 1994-11-30 1994-11-30

Publications (1)

Publication Number Publication Date
YU20095A true YU20095A (sh) 1998-08-14

Family

ID=27499246

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20095A YU20095A (sh) 1994-03-31 1995-03-30 Mgdf polipeptidi i postupci za njihovu izradu

Country Status (32)

Country Link
US (1) US5766581A (sh)
EP (3) EP0755263A4 (sh)
JP (2) JP2996415B2 (sh)
KR (2) KR100203824B1 (sh)
CN (2) CN1103782C (sh)
AT (1) ATE169335T1 (sh)
AU (1) AU691606B2 (sh)
BG (1) BG62685B1 (sh)
BR (1) BR9506017A (sh)
CA (1) CA2167090C (sh)
CZ (2) CZ288926B6 (sh)
DE (1) DE69503849T2 (sh)
DK (1) DK0690127T3 (sh)
EE (1) EE9600121A (sh)
ES (1) ES2119250T3 (sh)
FI (1) FI960136A (sh)
GE (1) GEP20002180B (sh)
GR (1) GR3027593T3 (sh)
HK (2) HK1004231A1 (sh)
HU (1) HU218893B (sh)
IL (1) IL113206A0 (sh)
LV (2) LV11783B (sh)
MY (1) MY113048A (sh)
NO (1) NO960111L (sh)
NZ (1) NZ283863A (sh)
PL (1) PL182567B1 (sh)
RO (1) RO115788B1 (sh)
SI (1) SI0690127T1 (sh)
SK (1) SK166695A3 (sh)
TW (3) TW414799B (sh)
WO (1) WO1995026746A1 (sh)
YU (1) YU20095A (sh)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5986049A (en) * 1994-12-30 1999-11-16 Zymogenetics, Inc. Purified thrombopoietin and method of making it
TW387940B (en) * 1995-01-17 2000-04-21 Kirin Brewery Anti-tpo monodonal antibody
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
AU691410B2 (en) * 1995-02-15 1998-05-14 Amgen, Inc. MPL ligand analogs
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
CN1315870C (zh) 1995-06-07 2007-05-16 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
EP0870027A1 (en) * 1995-10-05 1998-10-14 G.D. Searle & Co. Novel c-mpl receptor agonists
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
CN1142940C (zh) * 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US5914251A (en) * 1996-10-22 1999-06-22 Amgen Inc. Nucleic acid molecules encoding placental-derived growth factors
AU2006201129B2 (en) * 1997-05-21 2008-03-13 Genentech, Inc. Novel administration of thrombopoietin
EP0983082A1 (en) * 1997-05-21 2000-03-08 Genentech, Inc. Novel administration of thrombopoietin
CZ298597B6 (cs) 1998-04-28 2007-11-21 Applied Research Systems Ars Holding N. V. Zpusob postupné vazby polyethylenglykolových skupin na polypeptid
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000057891A1 (en) 1999-03-30 2000-10-05 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60142239D1 (de) 2000-08-11 2010-07-08 Kyowa Hakko Kirin Co Ltd DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
AU2003276846A1 (en) * 2002-08-09 2004-02-25 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
ES2462916T3 (es) 2002-09-18 2014-05-26 Janssen Pharmaceuticals, Inc. Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
BRPI0407401A (pt) * 2003-02-11 2006-02-21 Irm Llc compostos bicìclicos e composições
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
MXPA05009429A (es) 2003-03-05 2005-12-12 Halozyme Inc Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7587286B2 (en) * 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
SI1675606T1 (sl) 2003-08-28 2017-07-31 Janssen Pharmaceuticals, Inc. Peptidi in spojine, ki se vežejo na trombopoietinske receptorje
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
RU2542391C2 (ru) 2003-12-30 2015-02-20 Аугустинус БАДЕР Способ регенерации ткани
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
US20060018875A1 (en) * 2004-06-14 2006-01-26 Blatt Lawrence M Interferon compositions and methods of use thereof
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
EP1768700B1 (en) * 2004-07-16 2010-12-15 Nektar Therapeutics Conjugates comprising gm-csf and a polymer
CA2583764C (en) 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8318153B2 (en) * 2006-06-29 2012-11-27 Nalin David R Method of medically treating an individual
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20100003238A1 (en) 2008-04-14 2010-01-07 Frost Gregory I Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP3037529B1 (en) 2008-12-09 2019-03-27 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof
EP2358790B2 (en) 2008-12-16 2016-09-21 Dow Corning Corporation Preparation of siloxanes
US20110294733A1 (en) 2009-01-20 2011-12-01 Hanall Biopharma Co., Ltd. Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP3127427B1 (en) 2009-05-29 2020-01-08 Novartis Ag Methods of administration of thrombopoietin agonist compounds
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
EP2771028A2 (en) 2011-10-24 2014-09-03 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
ES2727137T3 (es) 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2019015402A (es) 2017-06-22 2020-07-20 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
SG11202106244RA (en) 2018-12-28 2021-07-29 Catalyst Biosciences Inc Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
IL90719A0 (en) * 1988-06-28 1990-01-18 Yissum Res Dev Co Novel nuclei acids and polypeptides encoded thereby
US5128449A (en) * 1988-07-05 1992-07-07 The University Of Tennessee Research Corporation Polypeptide and a method for its production
DE68928138T2 (de) * 1988-09-21 1997-10-02 Meiji Seika Kaisha Neuer megakaryokytischer koloniestimulierender faktor und verfahren zur herstellung
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
AU641645B2 (en) * 1989-04-03 1993-09-30 Genetics Institute Inc. Megakaryocyte growth promoting activity
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DK0487613T3 (da) * 1989-08-08 1996-11-25 Genetics Inst Megakarycytopiesk faktor
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
EP0672684A1 (en) * 1990-05-31 1995-09-20 Meija Seika Kabushiki Kaisha, Ltd. Novel megakaryocyte colony stimulating factor and production thereof
JPH06502621A (ja) * 1990-07-02 1994-03-24 ヒップル　キャンサー　リサーチ　センター ヒトｍｅｇ―ｃｓｆタンパク質と方法
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0504361A4 (en) * 1990-10-05 1994-08-17 Systemix Inc Megakaryocyte and platelet growth, production and composition
JPH05503302A (ja) * 1990-10-12 1993-06-03 アムジエン・インコーポレーテツド 巨核球成熟因子
WO1992007074A1 (fr) * 1990-10-19 1992-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide de la famille d'un recepteur de facteur de croissance, application au diagnostic et a la therapie des maladies myeloproliferatives
AU646530B2 (en) * 1990-12-28 1994-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JPH04295500A (ja) * 1991-03-26 1992-10-20 Asahi Chem Ind Co Ltd 新規な巨核球増幅因子とその製法
EP0591420A1 (en) * 1991-06-28 1994-04-13 New England Deaconess Hospital A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
WO1993016106A1 (en) * 1992-02-07 1993-08-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
CN1148408A (zh) * 1994-02-14 1997-04-23 津莫吉尼蒂克斯公司 血细胞生成蛋白及其制造材料和方法
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995021626A1 (en) * 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets

Also Published As

Publication number Publication date
HK1041275B (zh) 2006-07-28
HK1004231A1 (en) 1998-11-20
TW414799B (en) 2000-12-11
ES2119250T3 (es) 1998-10-01
JP3485842B2 (ja) 2004-01-13
TW565568B (en) 2003-12-11
EE9600121A (et) 1997-04-15
GR3027593T3 (en) 1998-11-30
DE69503849T2 (de) 1999-04-01
CN1322759A (zh) 2001-11-21
LV11783A (lv) 1997-06-20
GEP20002180B (en) 2000-07-25
EP0675201A1 (en) 1995-10-04
FI960136A0 (fi) 1996-01-11
HU9600059D0 (en) 1996-03-28
HUT74257A (en) 1996-11-28
JP2000103799A (ja) 2000-04-11
DK0690127T3 (da) 1999-05-03
MY113048A (en) 2001-11-30
EP0690127A1 (en) 1996-01-03
LV12275A (lv) 1999-05-20
EP0755263A1 (en) 1997-01-29
EP0755263A4 (en) 2005-02-09
CZ288890B6 (cs) 2001-09-12
PL182567B1 (pl) 2002-01-31
BR9506017A (pt) 1997-10-14
JP2996415B2 (ja) 1999-12-27
NZ283863A (en) 1997-12-19
AU691606B2 (en) 1998-05-21
HK1041275A1 (en) 2002-07-05
WO1995026746A1 (en) 1995-10-12
IL113206A0 (en) 1995-06-29
HU218893B (hu) 2000-12-28
LV11783B (en) 1997-12-20
ATE169335T1 (de) 1998-08-15
CN1103782C (zh) 2003-03-26
CZ350595A3 (en) 1997-01-15
BG62685B1 (bg) 2000-05-31
EP0690127B1 (en) 1998-08-05
BG100625A (bg) 1997-04-30
KR100303810B1 (ko) 2001-12-01
RO115788B1 (ro) 2000-06-30
CA2167090C (en) 2002-05-14
FI960136A (fi) 1996-03-11
NO960111D0 (no) 1996-01-10
US5766581A (en) 1998-06-16
KR100203824B1 (ko) 1999-06-15
JPH10510980A (ja) 1998-10-27
CN1229385C (zh) 2005-11-30
CN1137757A (zh) 1996-12-11
SK166695A3 (en) 1997-02-05
AU2230895A (en) 1995-10-23
CZ288926B6 (cs) 2001-09-12
MX9600206A (es) 1998-11-30
DE69503849D1 (de) 1998-09-10
NO960111L (no) 1996-09-24
TW496870B (en) 2002-08-01
PL312577A1 (en) 1996-04-29
CA2167090A1 (en) 1995-10-12
SI0690127T1 (en) 1998-12-31
LV12275B (en) 1999-08-20

Similar Documents

Publication Publication Date Title
YU20095A (sh) Mgdf polipeptidi i postupci za njihovu izradu
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
DE69929313D1 (de) Verfahren und zusammensetzungen zur verabreichung von taxanen
DE69520499D1 (de) Histidine und homohistidine derivate zur verwendung als protein farnesyltransferase hemmstoffe
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE273384T1 (de) Tie-2 liganden, herstellungsverfahren und verwendung
BR9611571A (pt) Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
DE69924009D1 (de) Methode zur verstärkung der biologischen aktivität von liganden
HUP9900506A2 (hu) Protrombinszármazékok
RS50075B (sr) Postupak za proizvodnju heterolognih proteinskih supstanci u biljnom materijalu
DE602005027260D1 (de) Osteoblasten-zusammensetzung aus halbverfestigtem gemischtem fibrin zur agglutination von knochenfrakturen und herstellungsverfahren dafür
BR0009729A (pt) Dispersões de matéria sintética aquosas com estabilidade aumentada
DE69529229D1 (de) Verfahren und testsätze mit makrophagen stimulierenden proteinen
ATE421326T1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
DE69032471D1 (de) Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung
JPH03505732A (ja) 移動刺激因子